文献速递垂体与肾上腺疾病

肾上腺皮质癌合并显性库欣综合征的高皮质醇血症严重程度与管理

Severity and management of hypercortisolism in patients with adrenocortical carcinoma and overt Cushing´s syndrome.
PubMed 文献 · J Clin Endocrinol Metab · 2026-09-10

这项国际回顾性研究纳入101例肾上腺皮质癌(ACC)合并库欣综合征(CS)患者,分析基线高皮质醇血症程度与生存结局的关联。结果显示肾上腺肿瘤最大径和尿游离皮质醇(UFC)水平是转移性ACC的独立预测因素,且CS严重程度越高,复发/进展风险越高(轻度21%、中度52%、重度57%,P=0.035)。

要点

  • UFC水平和肾上腺肿瘤最大径是转移性ACC的独立预测因素。
  • CS严重程度越高,复发/进展风险越高(P=0.035)。
  • 高皮质醇血症强度可能作为侵袭性疾病的标志物。

核心结论

  • 肾上腺肿瘤大小和皮质醇过量严重程度与诊断时转移性疾病概率较高相关。
  • 皮质醇过量严重程度似乎与肿瘤复发/进展风险增加相关,提示高皮质醇血症强度可能作为侵袭性疾病的标志物。

研究设计与样本

  • 国际回顾性研究,纳入101例因肾上腺皮质癌(ACC)导致库欣综合征(CS)的患者。
  • 主要结局为评估基线高皮质醇血症对生存结局的预后作用,包括无进展生存期(PFS)、无病生存期(DFS)和总生存期(OS)。

主要发现

  • 诊断CS时尿游离皮质醇(UFC)中位水平为正常上限(ULN)的6.4倍(IQR 2.9-14),53.5%(n=54)的病例为转移性ACC。
  • 肾上腺肿瘤最大径(OR 1.02,95%CI 1.01-1.03)和UFC水平(OR 1.62,95%CI 1.03-2.57)是转移性ACC的独立预测因素。
  • 中位OS为19.4个月(范围1-176),中位DFS为12.3个月(范围2.6-143),中位PFS为5.6个月(范围1.1-43.7)。
  • 复发/进展风险随CS严重程度增加而升高:轻度高皮质醇血症(UFC<2×ULN)为21%,中度(2-5×ULN)为52%,重度(>5×ULN)为57%,P=0.035。
  • UFC水平(HR 1.48;95%CI 0.97-2.24,P=0.057)与进展风险(转移性ACC)呈边缘性关联趋势。

临床怎么用

  • 对于ACC合并CS患者,应评估UFC水平和肿瘤大小以识别转移高风险者。
  • 高皮质醇血症严重程度可作为侵袭性疾病的标志物,提示需密切监测复发/进展。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To analyze the association between the degree of hypercortisolism and survival outcomes of patients with Cushing´s syndrome (CS) due to adrenocortical carcinoma (ACC). METHODS: An international retrospective of patients with CS due to ACC. The primary outcomes were to evaluate the prognostic role of baseline hypercortisolism on survival outcomes, including progression-free survival (PFS), disease-free survival (DFS), and overall survival (OS). RESULTS: A total of 101 patients with ACC were included. The median urinary free cortisol (UFC) levels at the time of CS diagnosis were 6.4 times above the upper limit of normal (ULN) (IQR 2.9-14) and 53.5% (n = 54) of the cases had metastatic ACC. Maximum adrenal tumor size (OR 1.02, 95%CI 1.01-1.03) and UFC levels (1.62, 95%CI 1.03-2.57) were independent predictors of metastatic ACC. The median OS was 19.4 (range 1-176) months, the median DFS was 12.3 months (range 2.6-143), and PFS was 5.6 months (range 1.1-43.7). The risk of recurrence/progression increased as the severity of CS increased (21% in mild hypercortisolism (UFC <2xULN), 52% in moderate (2-5xULN) and 57% in severe CS (>5xULN), P = 0.035). UFC levels (HR 1.48; 95%CI 0.97-2.24, P = 0.057) tended to be associated with the risk of progression (metastatic ACC). When we considered a combined outcome (progression in metastatic ACC and recurrence in localized ACC), age, UFC, hypokalemia, R0 after surgery, and Ki-67 were independent predictors of recurrence/progression. CONCLUSION: Adrenal tumor size and the severity of cortisol excess are associated with a higher probability of metastatic disease at diagnosis. Our study suggests that the severity of cortisol excess appears to be associated with an increased risk of tumor recurrence/progression, suggesting that hypercortisolism intensity may serve as a marker of aggressive disease.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Araujo-Castro M, Bancos I, Detomas M, et al. Severity and management of hypercortisolism in patients with adrenocortical carcinoma and overt Cushing´s syndrome. J Clin Endocrinol Metab. 2026. PMID: 42717378. doi:10.1210/clinem/dgag373

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。